26122223|t|ANTIPSYCHOTICS REVERSE P-GLYCOPROTEIN-MEDIATED DOXORUBICIN RESISTANCE IN HUMAN UTERINE SARCOMA MES-SA/Dx5 CELLS: A NOVEL APPROACH TO CANCER CHEMOTHERAPY.
26122223|a|Multidrug resistance (MDR) mediated by P-glycoprotein (Pgp) remains one of the major obstacles to effective cancer chemotherapy. Several chemosensitizers have been used in vivo and in vitro to reverse MDR but have exhibited several unwanted side effects. Antipsychotics are often administered to treat psychiatric disorders such as delirium, anxiety and sleep disorders in cancer patients during chemotherapy. The present in vitro study, examined the effects of two common antipsychotic compounds, haloperidol and risperidone, and a natural compound such as theobromine on reversing MDR Pgp-mediated, to evaluate their potential use as chemosensitizing agents. The human doxorubicin (doxo) resistant uterine sarcoma cells (MES-SA/Dx5) that overexpress Pgp (100-fold), were treated with the antipsychotic alone (1, 10 and 20 muM) or in combination with different concentrations of doxo (2, 4 and 8 muM). The accumulation and cytotoxicity of doxo (MTT assay) and cellular GSH content (GSH assay) in comparison with verapamil, a well-known Pgp inhibitor, used as reference molecule were examined. It was found that the three compounds significantly enhanced the intracellular accumulation of doxo in resistant cancer cells, when compared with cells receiving doxo alone (p<0.05). Furthermore, compounds showed strong potency to increase doxo cytotoxicity toward resistant MES-SA/Dx5 cells, when compared with untreated control cells. The antipsychotic compounds also significantly increased GSH content at all concentrations (> 30%) in resistant cells, when compared to untreated control cells (p<0.05). These findings suggest that the antipsychotics or their derivatives might represent a novel class of reversal agents for overcoming MDR in cancer therapy, in particular theobromine showed to be an effective Pgp inhibitor with the lowest toxicity. 
26122223	23	38	P-GLYCOPROTEIN-	Disease	MESH:C565538
26122223	47	58	DOXORUBICIN	Chemical	MESH:D004317
26122223	73	78	HUMAN	Species	9606
26122223	79	94	UTERINE SARCOMA	Disease	MESH:D012509
26122223	95	101	MES-SA	CellLine	CVCL:1404
26122223	102	111	Dx5 CELLS	Disease	MESH:D002292
26122223	133	139	CANCER	Disease	MESH:D009369
26122223	140	152	CHEMOTHERAPY	Disease	MESH:D000084202
26122223	154	174	Multidrug resistance	Disease	MESH:D018088
26122223	176	179	MDR	Disease	MESH:D018088
26122223	193	207	P-glycoprotein	Gene	5243
26122223	209	212	Pgp	Gene	5243
26122223	262	268	cancer	Disease	MESH:D009369
26122223	355	358	MDR	Disease	MESH:D018088
26122223	456	477	psychiatric disorders	Disease	MESH:D001523
26122223	486	494	delirium	Disease	MESH:D003693
26122223	496	503	anxiety	Disease	MESH:D001007
26122223	508	523	sleep disorders	Disease	MESH:D012893
26122223	527	533	cancer	Disease	MESH:D009369
26122223	534	542	patients	Species	9606
26122223	627	650	antipsychotic compounds	Chemical	-
26122223	652	663	haloperidol	Chemical	MESH:D006220
26122223	668	679	risperidone	Chemical	MESH:D018967
26122223	712	723	theobromine	Chemical	MESH:D013805
26122223	737	740	MDR	Disease	MESH:D018088
26122223	741	744	Pgp	Gene	5243
26122223	819	824	human	Species	9606
26122223	825	836	doxorubicin	Chemical	MESH:D004317
26122223	838	842	doxo	Chemical	MESH:D004317
26122223	854	869	uterine sarcoma	Disease	MESH:D012509
26122223	877	883	MES-SA	CellLine	CVCL:1404
26122223	884	887	Dx5	CellLine	CVCL:2598
26122223	906	909	Pgp	Gene	5243
26122223	1034	1038	doxo	Chemical	MESH:D004317
26122223	1078	1090	cytotoxicity	Disease	MESH:D064420
26122223	1094	1098	doxo	Chemical	MESH:D004317
26122223	1100	1103	MTT	Chemical	MESH:C070243
26122223	1124	1127	GSH	Chemical	MESH:D005978
26122223	1137	1140	GSH	Chemical	MESH:D005978
26122223	1167	1176	verapamil	Chemical	MESH:D014700
26122223	1191	1194	Pgp	Gene	5243
26122223	1343	1347	doxo	Chemical	MESH:D004317
26122223	1361	1367	cancer	Disease	MESH:D009369
26122223	1410	1414	doxo	Chemical	MESH:D004317
26122223	1488	1492	doxo	Chemical	MESH:D004317
26122223	1493	1505	cytotoxicity	Disease	MESH:D064420
26122223	1523	1529	MES-SA	CellLine	CVCL:1404
26122223	1530	1539	Dx5 cells	Disease	MESH:D002292
26122223	1589	1612	antipsychotic compounds	Chemical	-
26122223	1642	1645	GSH	Chemical	MESH:D005978
26122223	1887	1890	MDR	Disease	MESH:D018088
26122223	1894	1900	cancer	Disease	MESH:D009369
26122223	1924	1935	theobromine	Chemical	MESH:D013805
26122223	1962	1965	Pgp	Gene	5243
26122223	1992	2000	toxicity	Disease	MESH:D064420
26122223	Negative_Correlation	MESH:D004317	MESH:D012509
26122223	Association	MESH:D018088	5243
26122223	Negative_Correlation	MESH:D004317	MESH:D002292
26122223	Negative_Correlation	MESH:D018967	5243
26122223	Negative_Correlation	MESH:D013805	MESH:D064420
26122223	Association	MESH:D012509	5243
26122223	Negative_Correlation	MESH:D013805	5243
26122223	Negative_Correlation	MESH:D006220	5243
26122223	Negative_Correlation	MESH:D014700	5243
26122223	Negative_Correlation	MESH:D004317	MESH:D009369
26122223	Association	MESH:D004317	5243
26122223	Negative_Correlation	MESH:D013805	MESH:D018088
26122223	Association	MESH:D004317	MESH:C565538
26122223	Negative_Correlation	MESH:D006220	MESH:D018088
26122223	Negative_Correlation	MESH:D004317	MESH:D018088
26122223	Association	MESH:D009369	5243

